Kilitch Drugs
323.50
+2.55(+0.79%)
Market Cap₹565.50 Cr
PE Ratio22.96
IndustryHealthcare
Company Performance:
1D+0.79%
1M+2.80%
6M-12.04%
1Y+4.71%
5Y+268.45%
View Company Insightsright
More news about Kilitch Drugs
13Aug 25
Kilitch Drugs Reports Robust Q1 Results with 131% Surge in Net Profit
Kilitch Drugs (India) Limited announced impressive Q1 FY2026 financial results. Consolidated net sales increased by 28.96% to ₹4,313.98 lakhs, while net profit surged by 130.94% to ₹226.25 lakhs. EBITDA grew by 37.55% to ₹582.20 lakhs, with the EBITDA margin improving to 13.50%. Standalone performance also showed growth, with net sales up 2.10% and net profit after tax increasing by 18.26%. The company's board has approved a rights issue of 13,968,463 equity shares at ₹357 per share, totaling ₹4,992.51 lakhs.
 no imag found
09Jul 25
Kilitch Drugs Announces Rights Issue at ₹357 Per Share
Kilitch Drugs' Board of Directors has approved a rights issue priced at ₹357.00 per share. This corporate action allows existing shareholders to purchase additional shares, potentially at a discount, to maintain their ownership percentage. The company aims to strengthen its capital base, though specific plans for the raised funds are not disclosed. Shareholders should await further details on the issue ratio, record date, and timeline.
 no imag found
20May 25
Kilitch Drugs Reports Impressive Q4 Results with Soaring Profits and Revenue
Kilitch Drugs announced impressive Q4 financial results, with net profit more than doubling to ₹104.40 crore from ₹46.80 crore year-over-year. The company's revenue surged to ₹563.00 crore, up from ₹391.00 crore in the same quarter last year. Sequentially, net profit also showed significant improvement, increasing from ₹56.50 crore in the previous quarter.
 no imag found
Kilitch Drugs
323.50
+2.55
(+0.79%)
1 Year Returns:+4.71%
Industry Peers
Sun Pharmaceutical
1,737.00
(-2.73%)
Divis Laboratories
6,408.50
(-1.01%)
Torrent Pharmaceuticals
4,333.30
(-1.51%)
Cipla
1,348.20
(-0.73%)
Dr Reddys Laboratories
1,286.30
(-2.50%)
Lupin
2,301.90
(-0.92%)
Mankind Pharma
2,247.60
(-1.41%)
Zydus Life Science
921.70
(-1.79%)
Aurobindo Pharma
1,220.40
(-0.02%)
Alkem Laboratories
5,639.50
(-1.96%)